The news directly pertains to PTC Therapeutics as the company's price target has been revised by Cantor Fitzgerald. While the Overweight rating is maintained, the lowering of the price target might indicate a slightly less optimistic outlook for the company's stock in the short term. However, the impact on the stock price is uncertain as the Overweight rating suggests that the analyst still expects the stock to outperform.